Risk of hypoglycaemia among people with type 2 diabetes not treated with insulin: A retrospective analysis of Medicare Advantage beneficiaries
Authors' conclusion
These findings show that HREs are prevalent in noninsulin-treated diabetes and identify a large number of patients who may benefit from CGM. Because >80% of HREs occur in the ambulatory setting and >70% occur in patients not taking sulfonylureas, primary care providers should be aware of the latest eligibility criteria for Medicare's coverage of CGM and not restrict this technology to their sulfonylurea-treated patients.
Study context
- Population
- Medicare Advantage beneficiaries with noninsulin-treated T2D, US healthcare claims, January 2007 to March 2023
- Participants
- 3,229,695 beneficiaries
- Outcome
- Hypoglycaemia-related encounters (HREs) after first T2D-related claim, by setting (ambulatory or inpatient/ED)
Methodological detailsclaims database analysis, Optum's deidentified Clinformatics® database
- Claims database analysis
- Optum's deidentified Clinformatics® database
Main finding
As reported in the abstract
Beneficiaries with hypoglycaemia-related encounters (HREs)
689,853
21.4%
Of those, ≥1 HRE in an ambulatory location
82.9%
n = 571,581
Of those, ≥1 HRE in an ED/inpatient location
26.8%
n = 184,833
Observational data: associations, not effects.
Further findings
Strongest predictors of an HRE
- Use of SU, OR
- 4.33 (4.27-4.38) (CI)
- End-stage kidney disease, OR
- 2.87 (2.79-2.94) (CI)
- Hypertension, OR
- 3.09 (3.04-3.15) (CI)
- Retinopathy, OR
- 2.94 (2.82-3.07) (CI)
- P value
- P < 0.001
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →